Paclitaxel nanoparticles - Pharma in silica
Alternative Names: OpPacli™; optimized paclitaxel - Pharma in silica; Paclitaxel associated silica based nanoparticles - Pharma in silicaLatest Information Update: 04 Aug 2023
At a glance
- Originator Pharma in silica
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Non-small cell lung cancer; Solid tumours